clinical research

Cannabis Operators Pivot Strategy as Schedule III Decision Looms

Cannabis companies are pursuing clinical trial partnerships and expansion strategies in anticipation of marijuana's potential rescheduling to Schedule III, even as the DEA's final decision timeline remains uncertain.